Valuation: Haleon plc

Market Cap 29.45B 39.24B 35.19B 32.43B 55.74B 3,679B 57.3B 388B 155B 1,971B 147B 144B 6,231B P/E 2026 *
17.5x
P/E 2027 * 15.6x
Enterprise Value 36.57B 48.73B 43.7B 40.27B 69.22B 4,568B 71.15B 482B 192B 2,448B 183B 179B 7,738B EV / Sales 2026 *
3.24x
EV / Sales 2027 * 3.09x
Free-Float
98.31%
Yield 2026 *
2.4%
Yield 2027 * 2.63%
1 day+1.27%
1 week+2.89%
Current month+4.88%
1 month-4.07%
3 months-8.27%
6 months+1.15%
Current year-10.62%
1 week 329
Extreme 329
344.1
1 month 310.5
Extreme 310.5
433.6
Current year 310.5
Extreme 310.5
433.6
1 year 310.5
Extreme 310.5
433.6
3 years 274.4
Extreme 274.4
433.6
5 years 241.17
Extreme 241.1735
433.6
10 years 241.17
Extreme 241.1735
433.6
Manager TitleAgeSince
Chief Executive Officer 59 22/07/2021
Director of Finance/CFO 58 01/11/2024
Chief Tech/Sci/R&D Officer 63 01/08/2025
Director TitleAgeSince
Director/Board Member 59 23/05/2022
Chairman 71 01/01/2026
Director/Board Member 59 18/07/2022
Date Insider Type Main position Quantity % Market Cap. Importance
30/10/26 Buy

Director

7,670 0.0001%
22/9/26 Buy 2,139 0.0000%
22/9/26 Buy 12,209 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+1.27%+2.89%-7.74%+3.09% 39.24B
+1.44%+1.63%+48.17%+139.63% 1,276B
-0.47%+5.49%+49.03%+90.68% 676B
+0.20%+2.76%+34.37%+112.06% 519B
+0.17%+2.76%+44.07%+69.71% 388B
-0.48%+2.34%+70.66%+46.02% 365B
+0.76%+2.27%+31.59%+60.36% 307B
-1.29%+0.90%+5.77%+37.60% 287B
0.00%+0.86%+43.74%+74.04% 252B
+0.92%+2.03%+44.62%+125.07% 212B
Average +0.10%+2.39%+36.43%+75.83% 432B
Weighted average by Cap. -0.08%+2.51%+43.24%+96.29%

Financials

2026 *2027 *
Net sales 11.29B 15.04B 13.49B 12.43B 21.37B 1,410B 21.96B 149B 59.3B 756B 56.45B 55.25B 2,388B 11.67B 15.54B 13.94B 12.85B 22.08B 1,457B 22.7B 154B 61.29B 781B 58.34B 57.1B 2,468B
Net income 1.67B 2.22B 1.99B 1.84B 3.16B 208B 3.25B 22B 8.77B 112B 8.34B 8.17B 353B 1.83B 2.43B 2.18B 2.01B 3.46B 228B 3.55B 24.09B 9.6B 122B 9.14B 8.94B 387B
Net Debt 7.12B 9.49B 8.51B 7.84B 13.47B 889B 13.85B 93.87B 37.4B 476B 35.6B 34.84B 1,506B 6.63B 8.83B 7.92B 7.3B 12.55B 828B 12.9B 87.4B 34.82B 444B 33.15B 32.44B 1,403B
Projected Income Statement - Annual - Haleon plc
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (31.4%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - pain relief medicines (23.2%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - respiratory medicines (17%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (15.3%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc.; - medicines for digestive health (8.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - other (4.2%). Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (41.6%), North America (35.1%), and Asia/Pacific (23.3%).
Employees
24,535
Date Price Change Volume
10/11/26 GBX 335.00 +1.27% 49,235,014
09/11/26 GBX 330.80 -2.39% 59,983,553
06/11/26 GBX 338.90 -0.53% 41,825,204
05/11/26 GBX 340.70 +0.92% 76,891,722
04/11/26 GBX 337.60 +3.69% 41,596,752
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Haleon plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.350GBP
Average target price
3.759GBP
Spread / Average Target
+12.21%